Anemia como fator preditivo negativo de resposta ao tratamento do câncer de colo uterino / Anemia as a negative predictive factor for response to treatment of cervical cancer

Authors

  • Luciano de Souza Viana
  • Harley Francisco de Oliveira
  • Henrique Hott Fernandes
  • Isabela de Sousa Martins
  • Larissa de Araújo Franco
  • Lígia Machea Duarte
  • Natália Quintão Barros

DOI:

https://doi.org/10.34117/bjdv7n12-047

Keywords:

Câncer de colo do útero, Baixa hemoglobina, Prognóstico, Radioterapia.

Abstract

Introdução: No Brasil, o câncer cervical (CC) é o terceiro tumor maligno mais frequente nas mulheres e a quarta causa de morte por câncer entre a população feminina, de acordo com o Instituto Nacional do Câncer (INCA). O agrupamento TNM, o tipo e grau histológico, a invasão linfovascular e/ou perineural são fatores prognósticos independentes, assim como a anemia. Objetivos: O presente estudo analisou o risco de óbito no primeiro ano de seguimento oncológico após término da radioterapia, conforme nível de hemoglobina (HB) pré tratamento (<10g/dl vs ≥10g/dl). Método: Estudo tipo coorte retrospectiva que incluiu pacientes com diagnóstico de CC, admitidas e tratadas em centro especializado de oncologia de Ipatinga - MG, Brasil no período de 2014 a 2017. Resultados: Pacientes com HB ≥ 10g/dl no pós tratamento apresentaram menor chance de evoluir para o óbito com relação às pacientes com HB < 10g/dl. 66,1% dos pacientes com HB ≥ 10g/dl no baseline foram classificados como livre da doença após término da radioterapia. O valor da HB após término da radioterapia também foi preditivo de resposta à radioterapia. Conclusão: A presença de HB < 10g/dl após término do tratamento correlacionou-se negativamente com tipo de resposta e risco de óbito.

References

BISHOP, A. J., et al. Relationship between low hemoglobin levels and outcomes after treatment with radiation or chemoradiation in patients with cervical cancer: Has the impact of anemia been overstated? International Journal of Radiation Oncology Biology Physics, 2015. 91(1), 196-205.

CAO, Wei et al. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020. Chinese Medical Journal, v. 134, n. 7, p. 783, 2021.

DUNST J, et al. Anemia in cervical cancers; impact on survival, patterns of relapse, and association with hypoxia and angiogenesis. Int J Radiat Oncol Biol Phys 2003; 56: 778–87.

FYLES A.W., et al. Anemia, hypoxia and transfusion in patients with cervical cancer: A review. Radiother Oncol 2000; 57: 13–9.

GILLIAN, Thomas; ALI,Shamshad; HOEBERS, J P, et al. Phase III trial to evaluate the efficacy of maintaining hemoglobin levels above 12.0 g/dL with erythropoietin vs above 10.0 g/dL without erythropoietin in anemic patients receiving concurrent radiation and cisplatin for cervical cancer. Gynecol Oncol. 2008;108(2):317-325. doi:10.1016/j.ygyno.2007.10.011.

GROGAN M. et al. The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix. Cancer 1999; 86: 1528–36.

INCA. Instituto Nacional do Câncer. Tipos de câncer: câncer do colo uterino. 2021.

KRYSTYNA S., ANDRZEJ B. & JACEK J. Clinical relevance of hemoglobin level in cervical cancer patients administered definitive radiotherapy, Acta Oncologica, 2006. 45:6, 695-701.

KOULIS, A. T. et al. Anemia, leukocytosis and thrombocytosis as prognostic factors in patients with cervical cancer treated with radical chemoradiotherapy: A retrospective cohort study. Clin Transl Radiat Oncol. 2017. 12: 51-56.

MARANGA IO, et al. Analysis of Factors Contributing to the Low Survival of Cervical Cancer Patients Undergoing Radiotherapy in Kenya. PLoS ONE 2013. 8(10): e78411.

MINISTÉRIO DA SAÚDE. Saúde amplia vacinação contra HPV para mulheres imunossuprimidas com até 45 anos. 2021 . Disponível em: <https://www.gov.br/saude/pt-br/assuntos/noticias/saude-amplia-vacinacao-contra-hpv-para-mulheres-imunossuprimidas-com-ate-45-anos>. Acesso em: 23 de setembro, 2021.

ROFSTAD EK, et al. Hypoxia-induced treatment failure in advanced squamous cell carcinoma of the uterine cervix is primarily due to hypoxia-induced radiation resistance rather than hypoxia-induced metastases. Br J Cancer 2000; 83: 354–9.

SHIN, N. et al. Prognostic value of pretreatment hemoglobin level in patients with early cervical cancer. Obstetrics & Gynecology Science. 2014. 1: 28-36.

SUNG, Hyuna et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians, v. 71, n. 3, p. 209-249, 2021.

VIAS, P. et al. A prospective study comparing hemoglobin levels and response in patients of locally advanced carcinoma cervix receiving accelerated chemoradiation versus conventional chemoradiation. Journal of radiation and cancer research. 2019. 3 (10): 135-140.

WORLD HEALTH ORGANIZATION. Clinical Transfusion Practice Guidelines for Medical Interns. 2 ed. Bangladesh: World Health Organization; 2020. 42p.

WORLD HEALTH ORGANIZATION. WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention. 2 ed. Geneva: World Health Organization; 2021. 97p

YADDANAPUDI, S; YADDANAPUDI, LN. Indications for blood and blood product transfusion. Indian J Anaesth. 2014. 58 (5): 538-542.

YANAZUME, S. et al. Tumor bleeding requiring intervention and the correlation with anemia in uterine cervical cancer for definitive radiotherapy. Jpn J Clin Oncol. 2018. 48: 892-899.

Published

2021-12-29

How to Cite

Viana, L. de S., Oliveira, H. F. de, Fernandes, H. H., Martins, I. de S., Franco, L. de A., Duarte, L. M., & Barros, N. Q. (2021). Anemia como fator preditivo negativo de resposta ao tratamento do câncer de colo uterino / Anemia as a negative predictive factor for response to treatment of cervical cancer. Brazilian Journal of Development, 7(12), 110792–110805. https://doi.org/10.34117/bjdv7n12-047

Issue

Section

Original Papers